Therefore, ICM hearts of ischemic origin might not be able to compensate as effective as do DCM patients by upregulating Mstn to maintain oxidative metabolism [7] and by regulating their IGF-I signaling to counter-act the decreased contractility [11]. This evidence concerns the gene IGF1 and familial dilated cardiomyopathy.